NAUT vs. TRNS, SENS, CTKB, LAB, ALNT, EYPT, AEHR, QTRX, QSI, and KEQU
Should you be buying Nautilus Biotechnology stock or one of its competitors? The main competitors of Nautilus Biotechnology include Transcat (TRNS), Senseonics (SENS), Cytek Biosciences (CTKB), Standard BioTools (LAB), Allient (ALNT), EyePoint Pharmaceuticals (EYPT), Aehr Test Systems (AEHR), Quanterix (QTRX), Quantum-Si (QSI), and Kewaunee Scientific (KEQU). These companies are all part of the "measuring and control equipment" industry.
Nautilus Biotechnology vs.
Transcat (NASDAQ:TRNS) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap computer and technology companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, community ranking, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.
Transcat received 207 more outperform votes than Nautilus Biotechnology when rated by MarketBeat users. Likewise, 66.14% of users gave Transcat an outperform vote while only 19.05% of users gave Nautilus Biotechnology an outperform vote.
98.3% of Transcat shares are held by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are held by institutional investors. 2.3% of Transcat shares are held by company insiders. Comparatively, 40.5% of Nautilus Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Transcat has a net margin of 6.22% compared to Nautilus Biotechnology's net margin of 0.00%. Transcat's return on equity of 7.23% beat Nautilus Biotechnology's return on equity.
Transcat has higher revenue and earnings than Nautilus Biotechnology. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.
Transcat has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Nautilus Biotechnology has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500.
In the previous week, Nautilus Biotechnology had 1 more articles in the media than Transcat. MarketBeat recorded 2 mentions for Nautilus Biotechnology and 1 mentions for Transcat. Transcat's average media sentiment score of 1.68 beat Nautilus Biotechnology's score of 0.00 indicating that Transcat is being referred to more favorably in the media.
Transcat currently has a consensus price target of $111.50, indicating a potential upside of 33.41%. Nautilus Biotechnology has a consensus price target of $3.58, indicating a potential upside of 123.96%. Given Nautilus Biotechnology's higher probable upside, analysts clearly believe Nautilus Biotechnology is more favorable than Transcat.
Summary
Transcat beats Nautilus Biotechnology on 12 of the 16 factors compared between the two stocks.
Get Nautilus Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for NAUT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nautilus Biotechnology Competitors List
Related Companies and Tools
This page (NASDAQ:NAUT) was last updated on 2/21/2025 by MarketBeat.com Staff
Free NAUT Stock Alerts